Eneida Agosto-Colon, MD
Rheumatology · Jackson Heights, NYNPI 1629165162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $313,982 of the $420,058 with a category attached, or 74.7%. 33 manufacturers reported payments, led by AbbVie at 44.7% of the total. Reporting peaked in 2019 at $133,732 and has fallen 56.1% since, to $58,711 in 2025. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,647 payments — averaging $255.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$188K
- Amgen$68K
- AstraZeneca$43K
- Mallinckrodt Enterprises LLC$29K
- Novartis$21K
- GSK$19K
- plus $52K from 27 others
Across 5 payments — averaging $832.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
What the payments were for
- Consulting fees$25,5266%
- Speaking & faculty fees$313,98275%
- Travel & lodging$42,46910%
- Food & beverage$37,7589%
- Education$3230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 514 | $187,668 |
| Amgen(2 entities) | 277 | $68,277 |
| AstraZeneca(2 entities) | 110 | $42,693 |
| Mallinckrodt Enterprises LLC | 36 | $28,823 |
| Novartis | 130 | $21,336 |
| GSK | 55 | $19,051 |
| Johnson & Johnson | 84 | $15,025 |
| Regeneron Healthcare Solutions, Inc. | 22 | $9,503 |
| Bristol Myers Squibb | 45 | $9,314 |
| Mallinckrodt Hospital Products Inc. | 33 | $7,289 |
| Aurinia Pharma U.S., Inc. | 33 | $3,658 |
| Pfizer | 96 | $1,419 |
| UCB, Inc. | 36 | $1,236 |
| Sanofi | 14 | $1,106 |
| ANI Pharmaceuticals, Inc. | 45 | $865 |
| Lilly USA, LLC | 32 | $635 |
| Merz North America, Inc. | 1 | $300 |
| Radius Health, Inc. | 9 | $254 |
| Boehringer Ingelheim | 9 | $238 |
| Cumberland Pharmaceuticals, Inc. | 7 | $225 |
| IBSA Pharma Inc. | 10 | $205 |
| E.r. Squibb & Sons, L.L.C. | 9 | $186 |
| Scilex Pharmaceuticals Inc. | 23 | $165 |
| Revance Therapeutics, Inc. | 1 | $148 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $115 |
| Tonix Medicines, Inc. | 2 | $77 |
| Arcutis Biotherapeutics, Inc. | 3 | $61 |
| Genentech USA, Inc. | 3 | $58 |
| Sandoz | 2 | $41 |
| Medexus Pharma, Inc. | 2 | $28 |
| Sobi, Inc | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$420,058 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 18 | $1,356,404 |
| Enbrel SureclickEtanercept | 82 | $585,501 |
| Diclofenac Sodium | 1,069 | $433,727 |
| Humira(Cf) PenAdalimumab | 51 | $332,411 |
| RinvoqUpadacitinib | 44 | $268,957 |
| BenlystaBelimumab | 48 | $222,137 |
| Humira(Cf)Adalimumab | 24 | $182,597 |
| KevzaraSarilumab | 43 | $174,295 |
| Xeljanz XrTofacitinib Citrate | 24 | $132,080 |
| VraylarCariprazine Hcl | 64 | $92,672 |
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $91,863 |
| RestasisCyclosporine | 142 | $91,517 |
| Orencia ClickjectAbatacept | 16 | $90,216 |
| Lidocaine | 472 | $84,483 |
| Fluocinonide | 526 | $81,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Vraylar, Restasis, Savella | $187,668 | $664,570331 claims |
| AmgenProlia, Evenity (2 Syringes), Pennsaid, Vimovo | $68,277 | $243,032117 claims |
| GSKBenlysta | $19,051 | $222,13748 claims |
| SanofiKevzara | $1,106 | $174,29543 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,236 | $91,86317 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $165 | $67,487146 claims |
| Radius Health, Inc.Tymlos | $254 | $61,23624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.
Other rheumatology in Jackson Heights
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
- Sanjay GodhwaniWading River$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.